United Therapeutics develops and commercializes products for chronic and life-threatening diseases. Products include Tyvaso DPI, Tyvaso, Remodulin, Orenitram, Adcirca, Unituxin, and Remunity Pump. The company also develops RemoPro, Ralinepag, Aurora-GT, and Nebulized Tyvaso. Licensing agreements include DEKA Research, MannKind Corporation, and Arena Pharmaceuticals. The company was incorporated in 1996 and is headquartered in Maryland.
| Indicator | Value |
|---|---|
| PER | 18.7 |
| EV/EBITDA | - |
| Price/Free Cash Flow' | 24.1 |
| ROIC | -% |
| Net Debt/EBITDA | - |